Apple Inc. has formally appealed a recent regulatory ban on the blood oxygen monitoring feature of its popular Apple Watch, marking the latest chapter in an ongoing legal and technological dispute over wearable health devices. The ban, imposed by health authorities citing concerns over accuracy and compliance, has sparked debate about the future of consumer health technology and Apple’s role as an innovator.

Introduced in 2020, the Apple Watch’s blood oxygen (SpO2) monitoring feature quickly became a standout health tool, allowing users to measure their blood oxygen saturation levels non-invasively. This capability has been widely praised for its potential to aid in early detection of respiratory issues, sleep apnea, and overall wellness tracking.

The ban was announced in mid-2025 by a leading regulatory body, which raised concerns about the device’s accuracy in clinical settings and its compliance with medical device regulations. Authorities argued that the Apple Watch’s SpO2 readings could not be relied upon for diagnostic purposes and that the feature lacked necessary approvals for medical use.

Apple responded by emphasizing that the blood oxygen feature is intended for general wellness and fitness purposes, not as a medical device. The company highlighted its rigorous testing protocols, FDA clearance for certain health features, and ongoing efforts to improve accuracy through software updates.

The ban and Apple’s appeal have significant implications for millions of Apple Watch users who rely on the blood oxygen feature for health monitoring. If the ban remains, users may lose access to a key wellness tool, potentially impacting their ability to track respiratory health trends.

For the wearable tech industry, the case underscores the challenges of balancing innovation with regulatory compliance. It highlights the need for clear guidelines on health features in consumer devices and may influence how companies design and market such technologies in the future.